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Transcriptional repression through chromatin remodeling and
histone deacetylation has been postulated as a driving force for
tumorigenesis.We isolatedandcharacterizedanovelPOZdomain
Kru¨ppel-like zinc finger transcription repressor, ZBTB5 (zinc fin-
ger and BTB domain-containing 5). Serial analysis of gene expres-
sion (SAGE) analysis showed that ZBTB5 expression is higher in
retinoblastoma andmuscle cancer tissues. Immunocytochemistry
showed that ZBTB5 was localized to the nucleus, particularly
nuclear speckles. ZBTB5 directly repressed transcription of cell
cycle arrest gene p21 by binding to the proximal GC-box 5/6 ele-
ments and the two distal p53-responsive elements (bp 2323 
2299; bp 1416  1392). Chromatin immunoprecipitation
assays showed that ZBTB5 and p53 competed with each other in
occupying the p53 binding elements. ZBTB5 interacted with co-
repressor-histonedeacetylase complexes suchasBCoR(BCL-6-in-
teracting corepressor), NCoR (nuclear receptor corepressor), and
SMRT (silencing mediator for retinoid and thyroid receptors) via
its POZ domain. These interactions resulted in deacetylation of
histones Ac-H3 and Ac-H4 at the proximal promoter, which is
important in thetranscriptional repressionofp21.MTT(3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays and
fluorescent-activated cell sorter analysis revealed that ZBTB5
stimulatedbothcell proliferationandcell cycleprogression, signif-
icantly increasing the number of cells in S-phase. Overall, our data
suggest that ZBTB5 is a potent transcription repressor of cell cycle
arrest gene p21 and a potential proto-oncogene stimulating cell
proliferation.
The POZ domain,2 an evolutionarily conserved protein-pro-
tein interaction motif found in many regulatory proteins (1, 2),
was originally identified in Drosophila melanogaster bric-a`-
brac, tramtrack, and broad complex transcription regulators
and inmany pox virus zinc finger proteins (3, 4). Asmany as 184
known human proteins, 96 Drosophila proteins, and 137 Cae-
norhabditis elegans proteins are estimated to contain the POZ
domain (SMARTdata base). POZdomain proteins are involved
in many critical cellular processes such as apoptosis (5), devel-
opment (6, 7), ion channel activity (4), oncogenesis (8–10), and
transcription (10–16). In particular, some of the POZ domain
Kru¨ppel-like zinc finger (POK) proteins are the major determi-
nants of development, differentiation, and oncogenesis. For
instance, promyelocytic leukemia zinc finger (PLZF)-null mice
display severe defects in limb development and germ stem cell
maintenance (7, 17). Th-POK (T-helper-inducing POZ/Kru¨p-
pel-like factor, also known as cKrox) has been recently reported
as amaster regulator of T-cell lineage commitment (18). BCL-6
(B cell lymphoma transcription factor-6), PLZF, and HIC1
(Hypermethylated In Cancer) have been implicated in non-
Hodgkin lymphoma, acute promyelocytic leukemia, and spon-
taneous malignant tumors, respectively (8, 9, 19). Recently,
FBI-1 (also called Pokemon/LRF/ZBTB7A) was characterized
as a proto-oncogenic transcription factor regulating ARF and
Rb (retinoblastoma) genes (10, 20) and also as a critical deter-
minant of B versus T lymphoid lineage fate (21).
The most striking and common property of POZ domain
transcription factors is their ability to repress transcription
via theirPOZdomains (12–16,20), althougha fewactuallyactivate
transcription, such as FBI-1 and MIZ-1 in certain promoter con-
texts (22, 23). This characteristic probably underliesmany biolog-
icalprocessescontrolledby these factors.Theabilityof thedomain
to interact with other key regulatory proteins such as corepres-
sor proteins and other transcription factors appears to be
important for repression. In particular, the POZ domains of
human PLZF and BCL-6 have been shown to interact with
SMRT/N-CoR, mSin3A, BCoR, and histone deacetylase (12–
16, 20). Chromatin compaction by histone deacetylase complex
recruited by the POZ domain was suggested to repress tran-
scription in the case of PLZF-RARa fusion protein (13, 24, 26).
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The cyclin-dependent kinase inhibitor p21 is a major player
in cell cycle arrest in mammalian cells and the downstream
cell-cycle regulator of the ARF-HDM2-p53-p21 pathway (27–
29). The p21 gene, mainly regulated at the transcriptional level,
is a transcriptional target of tumor suppressor p53 and plays a
crucial role in mediating growth arrest when cells are exposed
to DNA-damaging agents (Ref. 29 and references therein).
Overexpression of p21 results in G1-, G2-, or S-phase arrest
upon exposure to DNA-damaging agents (30–32). Whereas
induction of p21 predominantly leads to cell cycle arrest,
repression of p21may have a variety of outcomes depending on
the cellular context (Ref. 29 and references therein). Aside from
p53, a variety of other factors including specificity proteins 1
and 3 (Sp1/Sp3), Smads, Ap2, STAT, BRCA1, E2F-1/E2F-3, and
C/EBP and - activate the transcription of p21 (29 and refer-
ences therein). In addition to its role responding to DNA dam-
age, p21 has also been implicated in terminal differentiation,
replicative senescence, and protection from p53-dependent
and -independent apoptosis (Ref. 29 and references therein).
Sp1 family transcription factors that bind at the proximal
promoter (bp120 to50) represent another group of major
regulators that affect p21 gene expression (Ref. 29 and refer-
ences therein). Sp1 is one of the best characterized transcrip-
tion factors that bind to GC-rich DNA sequences in numerous
cellular and viral genes (Refs. 33 and 34 and references therein).
The six Sp1 binding GC boxes of the p21 proximal promoter
have been shown to be important;mutation of the sites not only
significantly affects transcription but also disrupts synergistic
transcription activation by Sp1 and p53 and other signals that
regulate p21 gene transcription (29, 35). Among the six GC
boxes found in this region,GC-box 3mediates p21 induction by
various agents such as transforming growth factor-, butyrate,
the histone deacetylase inhibitor trichostatin A, lovastatin, and
Ca2. In contrast, GC-boxes 1 and 2 mediate transcriptional
activation by phorbol esters and okadaic acid, the tumor sup-
pressor protein BRCA1, and gut-enriched Kru¨ppel-like factor
(GKLF, KLF4). To date, no specific role has been attributed to
the most proximal and overlapping GC boxes 5 and 6 (Ref. 29
and references therein). Together, these observations suggest
that the specificity of utilizing different proximal GC-boxes
under different p21 regulation conditions is important.
From the analysis of amino acid sequences of all available
human POZ-domain proteins, we identified a novel ZBTB5
POK protein with a POZ-domain and two unique zinc finger
domains. We investigated whether ZBTB5 could regulate any
components of the ARF-HDM2-p53-p21 pathway and exam-
ined the mechanisms and physiological consequences of
ZBTB5 action. ZBTB5 repressed transcription of the p21 gene
and significantly increased cell proliferation. Our data suggest
that ZBTB5may be an important transcription regulator of p21
and may play a critical role in regulating important biological
processes controlled by p21.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents—p21-Luc plasmid was
kindly provided by Dr. Yoshihiro Sowa of the Kyoto Perpetual
University of Medicine (Kyoto, Japan). The various pGL2-
p21-Luc, pGL2-p53-Luc, pGL2-ARF-Luc, pGL2-HDM2-Luc,
pcDNA3.1-p53, pcDNA3.1-Sp1, pG5-5x(GC-box)-Luc, corepres-
sor expression vectors, andVP16-corepressors we used have been
reported elsewhere or were prepared by us (20, 23, 25). The
pcDNA3-ZBTB5 plasmid was prepared by cloning a cDNA frag-
ment (KIAA0354) into pcDNA3.0 (Invitrogen). The GAL4-
POZZBTB5 plasmid was prepared by cloning a cDNA fragment
(encoding amino acids 1–135) into a pCMX-Gal4 plasmid. To
prepare recombinant GST-POZZBTB5 and GST-ZFZBTB5 pro-
teins, cDNA fragments encoding the POZ domain (amino acids
1–123) and zinc fingers (amino acids 612–766) were cloned into
pGEX4T3 (Amersham Biosciences). All plasmid constructs were
verified by DNA sequencing.
Antibodies against p21, p53, Sp1, glyceraldehyde-3-phos-
phate dehydrogenase, FLAG tag, Ac-H3, Ac-H4, HDAC3, and
SMRT were purchased from Upstate (Charlottesville, VA),
Chemicon (Temecula, CA), Calbiochem, and Santa Cruz Bio-
technology (Santa Cruz, CA). Most of the chemical reagents
were purchased from Sigma.
Cell Cultures—HEK293A, HCT116 p53/, and CV-1 cells
were cultured in Dulbecco’s modified eagle medium (Invitro-
gen) supplemented with 10% fetal bovine serum (Invitrogen).
Saos-2 cells were cultured inMcCoy’s 5Amedium (Invitrogen)
supplemented with 15% fetal bovine serum.
Transcriptional Analysis of ARF-, HDM2-, p53-, p21-, and
p53-responsive Promoters—pGL2-ARF-Luc, pGL2-HDM2-
Luc, pGL2-p53-Luc, pG13-Luc, pG5-5x(GC-box)-Luc, and
various pGL2-p21-Luc promoter reporter fusion plasmids as
well as pcDNA3-ZBTB5, pcDNA3.1-p53, and pCMV-LacZ in
various combinations were transiently transfected into various
cell lines (HEK293A, HCT116, Saos-2, and CV-1) using Lipo-
fectamine Plus reagent (Invitrogen). After 24–36 h of incuba-
tion, cells were harvested and analyzed for luciferase activity.
Reporter activity was normalized with contransfected -galac-
tosidase activity for transfection efficiency.
Quantitative Real-time PCR of ZBTB5 mRNA Expression in
Cells and RT-PCR of Total RNA Prepared from FVB Mouse
Tissues—Total RNA was isolated from HEK293A cells using
TRIzol reagent (Invitrogen). cDNAs were synthesized using 5 g
of total RNA, randomhexamer (10 pmol), and Superscript reverse
transcriptase II (200units) in20l using a reverse transcriptionkit
(Invitrogen). qPCRwas performedusing SYBRGreenMasterMix
(Applied Biosystems). The following qPCR oligonucleotide prim-
ers sets were used: ZBTB5 forward, 5-CCACTAGTGACTGCA-
GGCTG-3, ZBTB5 reverse, 5-CCTGCATAGGCCTGACGAA-
3; p21 forward, 5-AGGGGACAGCAGAGGAAG-3, p21
reverse, 5-GCGTTTGGAGTGGTAGAAATCTG-3; GAPDH
forward, 5-CCCCTTCATTGACCTCAACTAC-3; GAPDH re-
verse, 5-TCTCGCTCCTGGAAGATGG-3.
To analyzeZBTB5mRNAexpression inFVBmouse, totalRNA
was isolated as described above from mouse brain, heart, liver,
muscle, kidney, spleen, brown adipose tissues, and white adipose
tissues, and RT-PCR was carried out using the following oligonu-
cleotide primer sets: ZBTB5 mRNA forward, 5-TTGCTGTTC-
ACAGCTGCCAC-3; reverse, 5-TTAGCCTGCGGGCCTTC-
CAC-3.
Western Blot Analysis—Cells were harvested and lysed in
radioimmune precipitation assay buffer (50 mM Tris-HCl, pH
8.0, 1% Nonidet P-40, 0.25% sodium deoxycholic acid, 150 mM
ZBTB5, Transcription Repressor of p21CIP1
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NaCl, 1 mM EDTA, Complete Mini-Protease mixture). Cell
extracts (40 g) were separated using 12% SDS-PAGE gel elec-
trophoresis, transferred onto Immun-BlotTM polyvinylidene
difluoride membranes (Bio-Rad), and blocked with 5% skim
milk (BD Biosciences). Blotted membranes were incubated
with antibodies against FLAG tag (Sigma), glyceraldehyde-3-
phosphate dehydrogenase (Chemicon), p21, p53, HDAC3,
ZBTB5, and SMRT and then incubatedwith anti-mouse or rab-
bit secondary antibody conjugated with HRP (Vector Labora-
tories). Protein bands were visualized with ECL solution
(PerkinElmer Life Sciences).
Knockdown of ZBTB5mRNA by siRNA—Four siRNA against
ZBTB5mRNAwere designed and purchased fromDharmacon
(Lafayette, CO): siZBTB5-1, 5-AACUUUACU-3 and 5-AGU-
AAAGUUAU-3; siZBTB5-2, 5-AGCUCGCAA-3 and 5-
UUGCGAGCUCC-3; siZBTB5-3, 5-UCCUCAUUU-3 and
5-AAAUGAGGACG-3; siZBTB5-4, 5-UAAUGGAUG-3
and 5-CAUCCAUUACA-3. siRNA (200 pmol) was trans-
fected into HEK293A cells using Lipofectamine 2000 (Invitro-
gen). After transfection, the cells were harvested, total RNAwas
prepared, and RT-qPCR analysis of mRNA was performed as
described above.
QuantitativeChromatin Immunoprecipitation (qChIP)Assays—
HEK293Acellswere transfectedwith increasing amounts of the
ZBTB5 expression vector pcDNA3-FLAG-ZBTB5. Themolec-
ular interaction between ZBTB5 and p53 or Sp1 on the endog-
enous p21 promoter and histone modification at the p21 prox-
imal promoter in the cells was analyzed by the standard qChIP
assay protocol, as described elsewhere (20, 23, 25).
Levels of ZBTB5 binding at p53RE-1, -2, and Sp1 binding
GC-box 5/6 sites were analyzed by anti-FLAG antibody
(Sigma), and levels of binding of endogenous Sp1 and p53 pro-
teins were analyzed by polyclonal antibodies against p53, and
Sp1 (Santa Cruz Biotechnology). As a negative control, qChIP
assays, IgG was used.
Quantitative PCR of chromatin immunoprecipitated DNA
was carried out using the following oligonucleotide primer sets
designed to amplify the upstream regulatory regions around
p53 binding sites and the proximal promoter region of the p21
gene: p53RE-1 binding primers (bp,23071947), forward
5-CTGTGGCTCTGATTGGCTTT-3, reverse 5-GGGTCT-
TTAGAGGTCTCCTGTCT-3; p53RE-2 binding primers (bp,
1462  1128), forward 5-CCACAGCAGAGGAGAAAG-
AAG-3, reverse 5-GCTGCTCAGAGTCTGGAAATC-3.
p21 proximal promoter primers (bp 133  30), forward
5-GCGCTGGGCAGCCAGGAGCCT-3, reverse 5-CTGA-
CTTCGGCAGCTGCTCAC-3. To analyze histoneH3 andH4
modification at the proximal promoter (bp,131100), for-
ward 5-GATCGGTACCGCGCTGGGCAGCCAGGAGCCT-
3, reverse 5-TCGTCACCCGCGCACTTAGA-3 primers
were used.
Immunoprecipitation Assays—HEK293A cells (transfected
with expression vector if necessary) were washed, pelleted, and
resuspended in a lysis buffer supplementedwith protease inhib-
itors (20 mM Tris-HCl, pH7.5, 150 mM NaCl, 10% glycerol, 1%
Triton X-100). Cell lysate was precleared, and the supernatant
was incubated overnight with anti-ZBTB5 (or anti-p53, anti-
Sp1 anti-Myc, anti-FLAG, anti-corepressor) antibody on a
rotating platform at 4 °C followed by incubation with protein
A-Sepharose Fast Flow beads. Beads were collected, washed,
and resuspended in equal volumes of 5 SDS loading buffer.
Immunoprecipitated proteins were separated with 12% SDS-
PAGE. The Western blot assay was performed as described
above using appropriate antibodies.
Mammalian Two-hybrid Assays—CV-1 cells were co-trans-
fected with pG5-Luc, pGal4-POZZBTB5, pVP16-corepressors,
and pCMV-LacZ using Lipofectamine Plus (Invitrogen). After
36 h of transfection, cells were harvested and assayed for lucif-
erase activity. Luciferase activity was then normalized with co-
transfected -galactosidase activity.
GST Fusion Protein Purification, in Vitro Transcription, and
Translation of Corepressors, p53, or Sp1, and Pulldown Assays—
Recombinant GST, GST-POZZBTB5, and GST-ZFZBTB5
fusion proteins were prepared from Escherichia coli BL21
(DE3) grown for 4 h at 37 °C in medium containing 1 mM iso-
propyl 1-thio--D-galactopyranoside. The E. coli were lysed
and purified using glutathione-agarose 4 bead affinity chromatog-
raphy (Peptron, Taejeon, Korea). The purified proteins were then
resolved with 12% SDS-PAGE to quantitate and assess purity.
Corepressor, p53, and Sp1 polypeptides were prepared by in-
cubating 1 g of pcDNA3-corepressor, pcDNA3.1-p53, or
pcDNA3.1-Sp1 expression plasmid with TNT Quick-coupled
Transcription/Translation Extract (Promega) containing 40 l of
TNT Quick Master Mix and 2 l of [35S]methionine (1175.0
Ci/mol) (PerkinElmer Life Sciences) at 30 °C for 90min. Polypep-
tide expression levels were then analyzed by running 1 l of the
total mixture through 12% SDS-PAGE and autoradiography.
For GST fusion protein pulldown assays, GST fusion protein-
agarose bead complexes were incubated with in vitro translated
[35S]methionine-labeled corepressors, p53, and Sp1 polypeptides
at 4 °C for 4 h in HEMG buffer (40 mM HEPES, 100 mM KCl, 0.2
mMEDTA, 5mMMgCl2, 0.1%Nonidet P-40, 10%glycerol, 1.5mM
DTT, protease inhibitors). The reaction mixtures were centri-
fuged, pellets were rinsed, and the bound proteins were separated
using 12% SDS-PAGE.Gels were then exposed to x-ray film using
an image-intensifying screen (Eastman Kodak Co.).
Preparation of Recombinant Adenovirus Overexpressing
ZBTB5—ZBTB5 cDNA was cloned into the adenovirus E1
shuttle vector pCA14 (Microbix; Ontario, Canada) to generate
pCA14-ZBTB5. The pCA14-ZBTB5 shuttle vector was linear-
ized by XmnI digestion, and the adenovirus vector vmdl324Bst
(from Dr. Verca at the University of Fribourgh, Switzerland),
containing the Ad5 genome deleted in the E1 and E3 region,
was also linearizedwith BstBI digestion. The linearized pCA14-
ZBTB5 and the vmdl324Bst digested with BstBI were co-trans-
formed into E. coli BJ518 for homologous recombination.
Proper homologous recombinant adenoviral plasmid was
digested with PacI and transfected into HEK293 cells to gener-
ate adenovirus expressing ZBTB5 (dl324-ZBTB5). Propagation
and titration of the recombinant virus was carried out by stand-
ard methods. PCR amplification and DNA sequencing using
primers specific to ZBTB5 confirmed the adenovirus genotype.
Electromobility Shift Assay (EMSA)—EMSAs were carried
out as described previously (20, 23, 25). The probe sequences of
Sp1 response elements on the p21 proximal promoter or the
sequences of p53 response elements on the p21 distal promoter
ZBTB5, Transcription Repressor of p21CIP1
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used in EMSA were as follows (only top strands are shown):
GC-box 1, 5-GATCGGGAGGGCGGTCCCG-3; GC-box 2,
5-GATCTCCCGGGCGGCGCG-3; GC-box 3, 5-GATCCG-
AGCGCGGGTCCCGCCTC-3; GC-box 4, 5-GATCCTTGA-
GGCGGGCCCG-3; GC-box 5/6, 5-GATCGGGCGGGGCG-
GTTGTATATCA-3; p53RE-1, 5-GATCCGTTAG-
AGGAAGAAGACTGGGCATGTCTG-3; p53RE-2, 5-
GATCCATCAGGAACATGTCCCAACATGTTGAGCTC-3.
Immunocytochemistry—HEK293A cells were transfected
with pcDNA3-FLAG-ZBTB5 plasmid, washed, and fixed with
cold methanol/formaldehyde. Cells were permeabilized,
washed, blocked with horse serum, and incubated with mouse
anti-FLAG primary antibody. After
thorough washing, cells were fur-
ther incubated with fluorescein iso-
thiocyanate-conjugated anti-mouse
IgG secondary antibody and, finally,
soaked with solution containing
4, 6-diamidino-2-phenylindole (1
mg/ml). The cells were mounted
and examined with a Carl Zeiss
LSM 510 confocal laser scanning
microscope.
Oligonucleotide Pulldown Assays—
HEK293A cells were lysed in
HKMG buffer (10 mM HEPES, pH
7.9, 100 mM KCl, 5 mM MgCl2, 10%
glycerol, 1 mM DTT, and 0.5% Non-
idet P-40). Cellular extracts were
incubated with 1 g of biotinylated
double-stranded oligonucleotides
(p53RE-1, p53RE-2, and Sp1–5/6)
for 16 h. The sequences of the oligo-
nucleotides are as follows (only top
strands are shown): Sp1–5/6, 5-
CCTTGAGGCGGGCCCGGGC-
GGGGCGGTTGTATATCAG-
GGC-3; p53RE-1, 5-GTCAGG-
AACATGTCCCAACATGTTGA-
GCTC-3; p53RE-2, 5-TAGAGG-
AAGAAGACTGGGCATGTCTG-
GGCA-3. To collect DNA-bound
proteins, the mixtures were incu-
bated with streptavidin-agarose
beads for 2 h, washed with HKMG
buffer, and precipitated by centrifu-
gation. The precipitate was ana-
lyzed by Western blot assay using
the antibody against ZBTB5 as
described above.
FACS Analysis—HEK293A cells
were transfected with ZBTB5
expression vector or siZBTB5 RNA.
The cells were washed, fixed with
methanol, and stained with solution
containing propidium iodide (50
g/ml) and ribonuclease A (100
g/ml) for 30 min at 37 °C in the
dark. DNA content, cell cycle profiles, and forward scatter were
analyzed with a FACSCalibur (BD Biosciences) flow cytometer
with emission detection at 488 nm (excitation) and 575 nm
(peak emission). Data were analyzed usingModFit LT 2.0 (Ver-
ity Software House, Inc.) and WindMDI 2.8 (Joseph Trotter,
Scripps Research Institute).
MTT Assay—Confluent HEK293A cells grown on 10-cm
culture dishes were transfected with ZBTB5 expression vec-
tor or siZBTB5 RNA, then transferred to 6-well culture
dishes and grown for 0–4 days. At 0, 1, 2, 3, and 4 days, cells
were incubated for 1 h at 37 °Cwith 20l/wellMTT (2mg/ml).
Precipitates were dissolved with 1 ml of dimethyl sulfoxide.
FIGURE 1. ZBTB5 represses transcription of the p21 andHDM2 genes in HEK293A cells. A, structure of the
ZBTB5 protein. Open box, POZ domain; numbered open circles, zinc fingers. a.a., amino acids. B, transcription
assays of p53 pathway genes by ZBTB5. ZBTB5 expression vector and promoter-luciferase fusion reporter
plasmid were transiently co-transfected into HEK293A cells, and luciferase activity was measured. C, Western
blot (WB) analysis of HEK293A cell lysates transiently transfected with ZBTB5 expression vector. GAPDH, con-
trol. D, RT-qPCR analysis of the total RNA isolated from HCT116 and HEK293A cells transfected with either
control adenovirus (dl324) or recombinant adenovirus (dl324-ZBTB5) overexpressing ZBTB5. E, RT-qPCR analy-
sis of the endogenous p21 and ZBTB5mRNA after HEK293A cells were transfected with three different siRNAs
targetingZBTB5ornonsilencing siRNA. KnockdownofZBTB5mRNAderepressedp21geneexpression. F,West-
ern blot analysis of HEK293A cell lysates transiently transfected with ZBTB5 siRNA. N.C., scrambled siRNA
negative control.
ZBTB5, Transcription Repressor of p21CIP1
JULY 24, 2009•VOLUME 284•NUMBER 30 JOURNAL OF BIOLOGICAL CHEMISTRY 19859
 at Y
O
N
SEI U
N
IV
ERSITY
 on January 20, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Cellular proliferation was deter-
mined from the conversion of MTT
to formazan using a SpectraMAX
250 (Molecular Device Co., Sunny-
vale, CA) at 570 nm.
Preparation of Anti-ZBTB5 Anti-
body—To obtain a rabbit polyclonal
antibody against ZBTB5 protein, a
white rabbit was immunized subcu-
taneously with a mixture of recom-
binant polypeptides, GST-POZ
(amino acids 1–123), and GST-
ZFDBD (amino acids 612–766) 7
times at 2-week intervals. Blood was
collected, incubated at 37 °C for 90
min, and centrifuged. The superna-
tant was incubated with the protein
A/G-agarose beads (SantaCruzBio-
technology). The beads were col-
lected andwashed, and the antibody
was eluted.
RESULTS
ZBTB5 Is a New BTB/POK Pro-
tein That Represses Transcription of
the p21 and HDM2Genes of the p53
Pathway—We isolated and charac-
terized a novel member of the
human POZ protein family, ZBTB5
(zinc finger and BTB domain-con-
taining 5 or KIAA0354), which
encodes a protein of 677 amino acid
residues. ZBTB5 has a POZ domain
at its N terminus (amino acids
1–123) and two zinc finger domains
at its C terminus (amino acids 613–
664) (Fig. 1A; supplemental Fig. 1).
Serial analysis of gene expression
(SAGE) analysis shows that ZBTB5
is expressed in most human tissues,
and our RT-PCR analysis of mouse
total RNA showed that mouse
Zbtb5 is also expressed ubiqui-
tously, with particularly high
expression in spleen and white adi-
pose tissues (supplemental Fig. 3B).
Immunocytochemistry revealed
nuclear localization of ZBTB5 (sup-
plemental Fig. 3C). Interestingly,
ZBTB5 is highly expressed in retina
and muscle cancer tissues (cgap.
nci.nih.gov).
Recently, several reports have
implicated POZ domain proteins
such as FBI-1, BCL-6, and Miz-1 in
cell cycle regulation, differentiation,
development, and oncogenesis (10,
20, 22). We investigated whether
FIGURE 2. ZBTB5 represses transcription of the p21 gene by acting on the distal regulatory element
containing p53 binding sites. A, structure of various p21 promoter constructs tested. B, transcription assays.
HEK293A cells were transiently co-transfected with ZBTB5 expression vector and pGL2-p21-Luc reporter plas-
mids with variable upstream sequences and analyzed for luciferase activity.
FIGURE 3. ZBTB5 represses transcription activation by p53. ZBTB5 binds to the distal p53 binding
elements and proximal GC-box 5/6 of the p21 gene. A, transcription analysis in HEK293A cells. Etoposide
treatment of the cells increased p21 gene expression, which was repressed by ZBTB5. kb, kilobases.
B, transcriptional activation of pGL2-6x(p53RE)-Luc by ectopic p53 was repressed by ZBTB5 in Saos-2 cells
lacking p53. p53RE, distal p53 binding element of p21. C, transcription analysis. HCT116 p53/ cells
lacking p53 were transiently co-transfected with a mixture of an expression vector of p53 and/or ZBTB5
and pGL2-p21-Luc wild type (2.3 kilobases), and luciferase activity was measured. D, EMSA. Two
[-32P]dATP-labeled p53RE-1 and -2 probes and Sp1 binding GC-box 5/6 probes were incubated with
GST-ZFZBTB5 (0.5 g) and separated by 4% nondenaturing PAGE. ZBTB5 bound to the distal p53 binding
elements and GC-box 5/6 of p21. ZFZBTB5, zinc finger DNA binding domain of ZBTB5. E, oligonucleotide
pulldown assay of ZBTB5 binding to the p53 binding elements and proximal GC-box 5/6. HEK293A cells
extracts were incubated with biotinylated double-stranded oligonucleotides. The mixtures were further
incubated with streptavidin-agarose beads and precipitated by centrifugation. The precipitate was ana-
lyzed by Western blot (WB) assay using antibodies against ZBTB5 and Sp1.
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ZBTB5 influenced expression of genes of the p53 pathway,
which are important in the regulation of cell cycle. ZBTB5
expression vector and various promoter-Luc fusion reporter
constructs were transiently co-transfected and analyzed for
reporter luciferase gene expression in HEK293A cells. ZBTB5
repressed transcription of p21 and HDM2 gene expression by
70 and 35%, respectively (Fig. 1B). The ectopic ZBTB5
expressed by plasmid or recombinant ZBTB5 adenovirus
repressed endogenous p21 gene transcription (Fig. 1, C andD).
Alternatively, knock-down of ZBTB5 mRNA by siRNA dere-
pressed endogenous p21 transcription inHEK293Acells (Fig. 1,
E and F). Overall, our data suggest that ZBTB5 is a transcription
repressor of p21 gene.
ZBTB5 Represses Transcription of Cell Cycle Arrest p21 Gene
and Repression by ZBTB5 Is Dependent on p53 Binding
Elements—We examined which regulatory elements of the p21
promoter were important for transcriptional repression of p21
byZBTB5 inHEK293Acells. AsZBTB5 repressed transcription
of the endogenous p21 gene (Fig. 1B). ZBZTB5 repressed tran-
scription of two different promoter constructs (1462 and
2307 bp) by 30–80%, and repression was particularly potent
with the2.3-kilobase promoter. Interestingly, ZBTB5was not
able to repress transcription of shorter promoter constructs
(864 and 131 bp) and instead significantly activated tran-
scription of p21 (190–310%). ZBTB5 transcription activation
was particularly potent with the shortest promoter construct
(131 bp), which is highly concentrated in Sp1 binding GC-
boxes (Fig. 2, A and B).
It appears that ZTB5 significantly repressed transcription of
the p21 promoter bearing a 2.3-kilobase upstream sequence
containing the two distal p53-binding sites but that repression
was somewhat weak with the1.5-kilobase construct with one
p53 binding element. These data suggest that transcriptional
repression by ZBTB5 may involve p53 and distal p53 binding
elements.
ZBTB5 Represses Transcriptional Activation of p21 by p53
and Binds to the p53 Binding Elements and Proximal Sp1 Bind-
ing GC-box 5/6—Because ZBTB5 only significantly repressed
transcription of the promoter with distal p53 binding sites, we
suspected that the repression mechanisms involved p53 and
distal p53 binding elements. We investigated whether ZBTB5
could block the transcriptional activation of p21 by etoposide-
activated p53 or by ectopic p53 in HEK293A cells and HCT116
p53/ cells lacking p53. In HEK293A cells, treatment with the
DNA-damaging agent etoposide increased p21 gene expression
by inducing p53,whichwas again repressed byZBTB5 (Fig. 3A).
Additional transcriptional analysis of pG5–6x(p53RE)-Luc
with five copies of p53 binding elements of the p21 gene in the
proximal promoter showed that ZBTB5 blocked transcription
activation by p53 in Saos-2 cells (Fig. 3B). Ectopic p53 expres-
sion in HCT116 p53/ cells increased p21 gene expression,
which was repressed by ZBTB5 (Fig. 3C). Interestingly, ZBTB5
increased p21 gene expression in HCT116 p53/ cells, which
is relevant with the transcription activation of the short p21
promoter lacking p53 binding element in HEK293A cells
(Fig. 2B).
It is also important to note that ZBTB5 repressed transcrip-
tion without the induced or ectopic p53 in HEK293A cells on
the two promoter constructs (Fig. 3, A and B). These data sug-
gest that ZBTB5 may inhibit transcription of the p21 gene by
directly acting on the distal p53 binding elements. Indeed,
EMSA showed that the zinc finger DNA binding domain of
ZBTB5 can bind to p53RE-1 and -2 (Fig. 3,D and E). Moreover,
oligonucleotide pulldown assays showed that endogenous
ZBTB5 binds the elements (Fig. 3E). These results imply a
FIGURE 4. ZBTB5 competes with p53 in binding to the distal p53 binding
elementsand increasesSp1binding to theGC-box5/6 in vivo.A, structure
of the endogenous p21 gene. Distal p53 binding elements and proximal GC-
rich elements are indicated. Arrows indicate binding positions of the qChIP
oligonucleotide primers. Tsp 1, transcription start site. UTR, untranslated
region. B and C, qChIP assay of binding competition between p53 and FLAG-
ZBTB5on thedistal p53binding regions of endogenousp21 in HEK293A cells.
ZBTB5 competed with p53 in binding to the elements. The cells were trans-
fected with increasing amounts (0–6 g) of FLAG-ZBTB5 expression vector.
D, qChIP assay of FLAG-ZBTB5 and Sp1 binding on the proximal promoter
region of endogenous p21 in HEK293A cells. ZBTB5 increases Sp1 binding to
the elements. The cells were transfected with increasing amounts of FLAG-
ZBTB5 expression vector (0–6 g). Antibodies against FLAG tag, p53, Sp1,
and IgG were used in ChIP assays.
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potential binding competition between p53 and ZBTB5 on the
two p53 binding elements and that the binding competition
may be important in transcription repression. In addition,
ZBZTB5 also bound to the proximal Sp1 binding GC-box 5/6,
although relatively weakly compared with the p53 binding ele-
ments in EMSA (Fig. 3, D and E).
ZBTB5 and p53 Compete with Each Other in Binding to the
p53 Binding Elements, but ZBTB5 Dramatically Increases Sp1
Binding to the Proximal GC-box 5/6 of Endogenous p21 Gene—
We tested whether the ZBTB5 and p53 proteins compete for
sites on the endogenous p21 gene using quantitative ChIP
assays. A FLAG-ZBTB5 expression vector was transiently
transfected into HEK293A cells, and binding interactions were
analyzed on the p53RE-1 and -2 and the proximal GC boxes of
endogenous p21. ChIP assays using
antibodies against FLAG tag and
p53 revealed that ZBTB5 bound to
p53RE-1 and -2 by competing with
p53 in a dose-dependent manner
(Fig. 4, B and C). In contrast, qChIP
assays of binding of ZBTB5 and Sp1
on the proximal promoter of endog-
enous p21 revealed that ZBTB5 not
only binds to the region but also
dramatically increases Sp1 binding
to the region (Fig. 4D), which may
explain the synergistic transcription
activation on the short p21 pro-
moter construct.
Although the functional signifi-
cance of the binding of FLAG-
ZBTB5 to the proximal promoter
GC boxes in the short promoter
context remains unclear, our data
suggest that ZBTB5 may repress
transcription of the endogenous
p21 gene by binding competition
with p53, thus interfering with p53
binding onto the distal p53 binding
elements and communication
between p53 and proximal pro-
moter bound Sp1 on the endoge-
nous p21 gene.
ZBTB5 Interacts with p53 or
Sp1, and the Interaction May Be
Important in the Transcriptional
Regulation of p53 or Sp1 Target
Genes—Because transcription re-
pression or activation can be
achieved by protein-protein inter-
action between transcription fac-
tors, we investigated whether
ZBTB5 interacts with either p53 or
Sp1. Co-immunoprecipitation and
Western blot assays of HEK293A
cells transfectedwith FLAG-ZBTB5
expression vector revealed that
ZBTB5 and p53 or Sp1 interact with
each other in vivo (Fig. 5, B and E). The GST fusion protein
pulldown assay also showed that the GST-ZFZBTB5 domain
and GST-POZZBTB5 interacted with p53 or Sp1 in vitro, sug-
gesting that ZBTB5 interact directly with p53 or Sp1 (Fig. 5, C
and F).
To address the functional significance of such protein-pro-
tein interactions, we examined whether ZBTB5 affected tran-
scription activation by either p53 or Sp1 on artificial test pro-
moter constructs designed to analyze transcription activation
by the two factors. In the case of p53, as shown in the above,
transcriptional activation of p21 by p53 was repressed by
ZBTB5 (Fig. 3A and B). Furthermore, transcription of the p53-
responsive gene, pGL2-6x(p53RE)-Luc, which contains the p53
binding elements of p21, was repressed by ZBTB5 in Saos-2
FIGURE 5. ZBTB5 interacts directly with p53 and inhibits transcription activation of pG13-Luc by p53.
A, transcriptional activation of pG13-Luc by ectopic p53 can be repressed by ZBTB5 in Saos-2 cells. pG13
contains 13 copies of the p53-binding element. B, co-immunoprecipitation of ZBTB5 and p53. HEK293A cell
lysateswere immunoprecipitated (IP) using anti-ZBTB5 antibody and analyzed byWestern blotting (WB) using
anti-p53 antibody. The lysates were also immunoprecipitated by anti-p53 antibody and analyzed by Western
blottingusing anti-ZBTB5antibody.C, in vitroGST fusionproteinpulldownassays. Left, SDS-PAGEgel of recom-
binant GST, GST-ZFZBTB5, and GST-POZZBTB5 proteins. Right, recombinant GST, GST-POZZBTB5, or GST-
ZFZBTB5 was incubated with [35S]methionine-labeled p53, pulled down, and resolved by 10% SDS-PAGE. The gel
was thenexposed to x-ray film. Input, 10%of thep53added in thebinding reactions.D, transcriptional activationof
pG5-5x(GC-box)-Luc by Sp1 can be synergistically activated by ZBTB5 in HEK293A. pG5-5x(GC-box)-Luc contains
fivecopiesof theputativeSp1bindingsites.E, co-immunoprecipitationofZBTB5andSp1.HEK293Acell lysateswere
immunoprecipitated using anti-ZBTB5 antibody and analyzed by Western blotting using anti-Sp1 antibody. The
lysates were also immunoprecipitated by anti-Sp1 antibody and analyzed by Western blotting using anti-ZBTB5
antibody. F, in vitroGST fusion protein pulldown assays. Recombinant GST, GST-POZZBTB5, andGST-ZFZBTB5was
incubated with [35S]methionine-labeled Sp1, pulled down, and resolved by 10% SDS-PAGE. The gels were then
exposed to x-ray film. Input, 10%of the labeled Sp1 added in the binding reactions.
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cells (Fig. 3C).We observed similar results with pG13-Luc with
13 putative p53 binding sites (Fig. 5A). The data potentially
indicate that the protein interactions may contribute to inhib-
iting transcriptional activation by p53, probably by decreasing
p53 binding on the distal p53 binding elements (Fig. 4,B andC).
In contrast to p53, ZBTB5 syner-
gistically activated transcription on
the test promoter pG5-5x(GC-
box)-Luc, indicating that the Sp1-
ZBTB5 interaction might be an
important in synergistic transcrip-
tion activation (Fig. 5D). This dis-
covery is in line with transcription
activation of the short proximal
promoter of p21 (131 bp) by
ZBTB5 (Fig. 2B) and increased Sp1
binding by ZBTB5 (Fig. 4D) on the
proximal promoter of endogenous
p21 gene, which is loaded with six
Sp1 binding GC boxes.
The POZDomain of ZBTB5 Inter-
acts with the Corepressor-HDAC
Complex to Deacetylate Histones
Ac-H3 and Ac-H4 at the Proximal
Promoter of Endogenous p21—
ZBTB5 repressed transcription by
direct binding competition with p53
at the distal p53 binding elements
(Figs. 1B, 2B, 3, A and B, and Fig. 4, B
and C). Transcriptional repressors,
including some POZ-domain pro-
teins like PLZF and BCL-6, often
repress transcription through inter-
action with corepressors such as
SMRT, NCoR, BCoR, and mSin3A.
Mammalian two-hybrid assays in
HEK293A cells using pG5-Luc,
pGal4-POZZBTB5, and pVP16-core-
pressor fusion protein expression
vectors demonstrated that the POZ
domain interacted with SMRT,
BCoR, and NCoR (Fig. 6A). Co-im-
munoprecipitation andWestern blot
analysis of HEK293A cell extracts or
HEK293A cell extracts transfected
withFLAG-ZBTB5expression vector
using anti-SMRT co-repressor and
anti-HDAC3 antibodies revealed that
ZBTB5 interactedwith BCoR,NCoR,
SMRT, and HDAC3 in vivo (Fig. 6B),
indicating that ZBTB5 may inhibit
transcription on the p21 proximal
promoter by interacting with the co-
repressor-HDAC complex via its
POZdomain. In addition,GST fusion
protein pulldown assays using the
recombinant GST-POZZBTB5 pro-
tein and in vitro translated
[S35]methionine labeled co-repressor polypeptides showed that
the POZ domain of ZBTB5 can interact directly with SMRT,
BCoR, and NCoR (Fig. 6C).
Corepressor complexes recruited by transcriptional repres-
sors often containHDACproteins, and ZBTB5 fits this pattern.
FIGURE 6. The POZ domain of ZBTB5 interacts directly with corepressors SMRT, NCoR, and BCoR, and
ZBTB5-corepressor-HDAC complexes deacetylate histones Ac-H3 and Ac-H4. A, mammalian two-hybrid
assays of protein-protein interactions between the POZ-domain and corepressor proteins. HEK293A cellswere
transfectedwith pG5-Luc, pGal4-POZZBTB5, andpVP16-corepressor expression plasmids, and luciferase activ-
ity was measured. B, co-immunoprecipitation of ZBTB5, BCoR, NCoR, SMRT, and HDAC3. Cell lysates prepared
fromHEK293Acells orHEK293A transfectedwith FLAG-ZBTB5expression vectorwere immunoprecipitated (IP)
using anti-FLAG or ZBTB5 antibody and analyzed byWestern blotting (WB) using anti-Myc-BCoR, NCoR, SMRT,
andHDAC3antibodies.C, in vitroGST fusionproteinpulldownassays. RecombinantGSTorGST-POZZBTB5was
incubated with [35S]methionine-labeled corepressors, pulled down, and resolved by 10% SDS-PAGE. The gels
were then exposed to x-ray film. Input, 10% of the corepressors added in the binding reactions. D, trichostatin
A (TSA) treatment derepressed transcriptional repression of pG5-Luc by the Gal4-POZ ZBTB5 domain. Plasmid
mixtures of pG5-Luc and the pGal4-POZZBTB5expression plasmid were transiently co-transfected into
HEK293A cells. Trichostatin A treatment derepressed transcription of the reporter gene, implicating the
involvement of HDACs in transcriptional repression by ZBTB5. E, qChIP assays of histone modification at the
proximal promoter of the endogenous p21 gene using antibodies against Ac-H3 and Ac-H4. Cells were trans-
fected with FLAG-ZBTB5 and immunoprecipitated with the indicated antibodies, IgG, Ac-H3, or Ac-H4. ZBTB5
deacetylated histones Ac-H3 and Ac-H4 at the proximal promoter. UTR, untranslated region.
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These HDACs deacetylate the histones of nearby nucleosomes
to repress transcription. Treatment of HEK293A cells with the
HDAC inhibitor trichostatin A after co-transfection with pG5-
Luc, and pGal4-POZZBTB5 significantly affected transcrip-
tional repression by the POZ domain and resulted in a signifi-
cant increase in transcription (Fig. 6D). These data implicate
the involvement of HDACs in transcriptional repression by
ZBTB5.
Corepressor-HDACs recruited by ZBTB5 may deacetylate
the histones of nearby nucleosomes around the proximal pro-
moter. Accordingly, we used ChIP to examine whether the
acetylation status of histones H3 and H4 at the proximal pro-
moter of the endogenous p21 gene was altered by ZBTB5-core-
pressor-HDACs complexes in HEK293A cells transfected with
FLAG-ZBTB5 expression vector. The complex significantly
decreased acetylated histones H3 and H4 at the proximal pro-
moter of p21 by 40–65% (Fig. 6E).
ZBTB5 Stimulates Cell Proliferation and Increases the Num-
ber of Cells in S-phase—ZBTB5 potently repressed transcrip-
tion of p21, which is a major regulator of cell cycle arrest.
HEK293A cells transfectedwith ZBTB5 expression vector were
analyzed for cell cycle progression by FACS. ZBTB5 stimulated
cell cycle progression and increased the number of HEK293A
cells in S phase (21.3% in control
versus 31.2% in HEK293A-ZBTB5)
(Fig. 7A). Knockdown of endoge-
nous ZBTB5 mRNA by siZBTB5
RNA resulted in a decrease in the
number of cells in S-phase (31.0% in
control versus 24.6% in HEK293A-
ZBTB5) and a concomitant increase
in the number of cells in the G0-G1
phases (Fig. 7B). MTT assays
showed that overexpression of
ZBTB5 significantly increased cell
proliferation, and knockdown of
ZBTB5 mRNA by siRNA decreased
cell proliferation in HEK293A cells
(Fig. 7, C and D). Overall, our data
suggest that ZBTB5 potently stimu-
lates cell growth and proliferation
andmay be one of the major regula-
tors of cell proliferation by regulat-
ing p21 gene expression.
DISCUSSION
We found that ZBTB5 repressed
transcription of the p21 and HDM2
genes. Our investigation on tran-
scription regulation of the cell cycle
arrest gene p21 by ZBTB5 revealed
that p21 is the direct target of
ZBTB5. ZBTB5 regulates transcrip-
tion of the p21 gene through a
molecular mechanism that involves
p53 and the two upstream p53-re-
sponsive elements. ZBTB5 bound to
distal p53 binding elements by com-
peting with p53 and repressed the contribution of p53 to tran-
scription. The site has been shown to mediate the induction of
p21 gene expression by genotoxic stresses. Accordingly, DNA-
damaging signals that result in p53-medicated induction of p21
gene can be blocked by ZBTB5. Overall, these molecular fea-
tures of ZBTB5 may explain how ZBTB5 acts as a regulatory
protein of cell growth and proliferation and, potentially in
oncogenesis, by inhibiting p21 transcription.
ZBTB5 binds to the proximal Sp1 bindingGCbox 5/6, which
is a direct target of regulation by Sp1 and Sp family members.
Intriguingly, ZBTB5 binding to this particular site increased
transcription activation of short promoter by Sp1, although in
the much longer promoter context, ZBTB5 repressed tran-
scription of p21. In line with this finding, ChIP assays showed
that ZBTB5 significantly increases Sp1 binding to the proximal
promoter region, which may explain transcription activation
on the short proximal promoter.
Protein interaction between proximal promoter-bound Sp1
and distal p53 is important in the transcriptional activation of
the p21 gene, even in the basal level of p53. It appears that the
presence of p53 and p53 binding element affects the role of
ZBTB5 either as a transcription repressor or activator of the
p21 gene. Although ZBTB5 represses transcription of p21 in
FIGURE 7. ZBTB5 stimulates cell proliferation and increases the number of cells in S-phase. A, B, FACS
analysis of cell cycle progression. HEK293A cells were transfected with ZBTB5 expression vector or control
vector, cultured, and stainedwith propidium iodide. Cell proliferation was measured by FACS. Alternatively,
the cells were transfected with siRNA against ZBTB5 mRNA, and cell cycle progression was analyzed.
N.C., scrambled siRNA negative control. C,D, MTT assay of HEK293A cells grown for 1, 2, 3, and 4 days. The cells
were transfected with either control pcDNA3 vector or pcDNA3-FLAG-ZBTB5 expression vector and analyzed
for cell growth. Alternatively, the cells were treated with either negative control siRNA or siZBTB5 RNA. All
assays were performed in triplicate. Error bars are included but are too tight to see.
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the p53/HEK293A and HCT116 p53/ cells, ZBTB5 stim-
ulates transcription significantly, even on the longer p21 pro-
moter construct or endogenous p21 gene in HCT116 p53/
cells, probably by the molecular interaction between ZBTB5
and Sp1 on the proximal promoter.3 ZBTB5 may disrupt pro-
tein-protein interaction by Sp1 and p53 on the p21 gene to
repress transcription. This observation raised the possibility
that ZBTB5 is a unique POK family transcription regulator that
can act either as a positive or negative regulator of p21 tran-
scription depending on the cellular p53 status, i.e. mutation,
absence, or presence.
Based on our data, we propose a hypothetical model of tran-
scriptional regulation of p21 by ZBTB5 in p53-positive cells
(Fig. 8). Under normal cellular conditionswhere p53 expression
is low and ZBTB5 expression is absent or lower than Sp1, the
p21 gene is expressed in low basal levels driven by Sp1, and cells
proliferate normally. Challenge with a genotoxic stress induces
production of tumor suppressor p53, which binds to the distal
p53 responsive elements and activates transcription of p21 by
interacting with the Sp1 bound at the proximal GC boxes. The
induced p21 arrests cell cycle progression, allowing cells to
repair DNA damage. In cells without DNA damage where
ZBTB5 expression is high, ZBTB5 represses transcription
directly by binding to both the distal p53 binding elements and
proximalGC-box 5/6. ZBTB5bound to the regulatory elements
recruits the corepressor-HDAC complex, causing deacetyla-
tion of histone Ac-H3 and Ac-H4 around the proximal pro-
moter and repressing transcription.
When cells are under genotoxic stress andZBTB5 expression
is high or in cancerous tissues that have high levels of both p53
and ZBTB5, ZBTB5 represses transcription directly by binding
to both the distal p53 binding elements and proximal GC-box
5/6. Although p53 expression is also highly induced under these
conditions, p53 has to competewithZBTB5 to bind to the distal
p53 binding elements and is also affected by molecular interac-
tions between p53 and ZBTB5 that further impede binding.
Although p53 is present, transcription of p21 is potently
repressed by ZBTB5. Cells proliferate without cell cycle arrest,
mutations accumulate, and cells are likely to undergo onco-
genic transformation (Fig. 8). These series of molecular events
may be important in the oncogenesis of retinoblastoma and
muscle cancer, where expression of ZBTB5 is high.3 D.-I. Koh and M.-W. Hur, unpublished data.
FIGURE 8. Hypothetical model of transcriptional regulation of cell cycle arrest gene p21 by ZBTB5. A, p53 pathway and ZBTB5 targets. ZBTB5 represses
transcription of the HDM2 and p21 genes. Solid line with arrowhead (3), transcriptional activation; solid line with, transcriptional repression. Solid line with
double arrowhead (7), molecular interaction. B, hypothetical model of transcriptional repression of p21 by ZBTB5 under three different cellular conditions.
ZBTB5 represses transcription of cell cycle arrest gene p21by binding to the two distal p53 binding elements by competitionwith p53. ZBTB5 also binds to the
proximal Sp1 binding GC-box 5/6, with an unclear function in the transcriptional repression of the endogenous p21 gene by ZBTB5. ZBTB5 recruits co-
repressor-HDAC complexes, which deacetylate histones Ac-H3 andAc-H4 at the proximal promoter to repress transcription. Tsp1, transcription start site. ZF,
zinc finger DNA binding domain., transcription repression.
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Although it can bind to the distal p53 binding elements to
repress transcription of p21, ZBTB5 also has characteristics of
Sp1 family Kru¨ppel-like zinc finger proteins and binds to some
of the GC boxes that are similar to the GC boxes recognized by
Sp1. Our findings suggest that some GC boxes recognized
by Sp1 may be transcriptional activation targets of ZBTB5 and
that Sp1-ZBTB5 binding competition or enhancement may be
a general mechanism of transcriptional regulation of some
ZBTB5 target genes.
Molecular interactions occurring both in the proximal and
distal promoter of the p21 gene are unique and may also be
applicable to the transcription regulation of other genes such as
HDM2. Indeed, theHDM2 gene has one binding site for p53 in
the P2 promoter region and is transcriptionally activated by
p53. In contrast, p21 has two p53 binding elements. The differ-
ence in the binding site number may explain why ZBTB5
repressed transcription of p21more potently.
In our laboratory we have observed that other POZ-domain
transcription factors such as FBI-1 (Pokemon), ZBTB2, and
PLZF repress transcription of p21 by acting on the distal p53
binding elements and proximal Sp1 binding GC-box.4 The
common theme of transcriptional regulation of cell cycle regu-
lator gene p21 by POZ-domain class transcription factors is
that distal p53 binding elements are the primary target sites of
transcription repression, which is eventually conveyed into the
histone deacetylation of the proximal promoter.
Although the molecular events involving ZBTB5 on the p53
binding elements are relatively straightforward, their action in
the short proximal promoter seems more complex, probably
because Sp1 familymembers,MIZ-1, c-Myc, BCL-6, FBI-1, and
ZBTB5 are integrated into the region to either activate or
repress transcription. ZBTB5 activates transcription by acting
on the short proximal promoter. ZBTB5 may act as transcrip-
tion activator in the region by interacting with transcription
regulators such as Sp family members andMIZ-1 that can bind
to the juxtaposed regulatory elements. The physiological
importance of the transcription activation of the short p21 pro-
moter (131 bp) by ZBTB5 is unclear at present because
ZBTB5 apparently represses endogenous p21 gene transcrip-
tion. Taken together, our findings indicate that ZBTB5 may
play a critical role in regulating important biological processes
such as DNA repair and cell growth, differentiation, and apo-
ptosis by regulating the transcription of p21 and HDM2 of the
p53 pathway.
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